Loading stock data…
RXRX
$3.39-0.07 (-2.02%)
Market ClosedLast close May 1
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Recursion Pharmaceuticals, Inc. in the Healthcare sector is trading at $3.39. The stock is currently near its 52-week low of $2.80, remaining 25.2% below its 200-day moving average. Technical signals show neutral RSI of 49 and bearish MACD signal, explaining why RXRX maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 49) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.39
Potential Upside
5%
Whystock Fair Value$3.56
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Buy
Mean target$6.57+93.8%
Range$3.00 – $10.00
Fundamentals
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.85B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.01
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-57.40%
Volume
Today's trading volume
12.16M
Recent News
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.41, indicating a -1.45% shift from the previous trading day.
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
Recursion Pharmaceuticals (RXRX) closed at $3.3 in the latest trading session, marking a -3.23% move from the prior day.
Recursion Pharmaceuticals (RXRX) Offers Encouraging Prospects After Setting 2026 Priorities
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 10 most shorted penny stocks to buy. The stock offers a 100% upside potential at the prevailing level, as of April 23 closing, based on its 1-year median price target of $7. This supports a moderately bullish consensus sentiment, with 1 Buy rating and 2 Hold calls. […]
Why Recursion Pharmaceuticals (RXRX) Is Down 7.1% After AI-Driven Trial Acceleration And Wider EPS Loss Forecast
Earlier this week, Recursion Pharmaceuticals reported that its AI-driven Recursion OS identified 25 drug targets simultaneously and helped cut clinical trial enrollment times by up to half, highlighting meaningful cost efficiencies across its development pipeline. The company also indicated that its upcoming quarterly results are expected to show an EPS loss of US$0.27 with revenue growing around 41% year over year, underscoring how rapid AI-enabled R&D advances are coinciding with ongoing...
A Look At Recursion Pharmaceuticals (RXRX) Valuation As AI Drug Discovery Progress And Earnings Expectations Gain Attention
Recursion Pharmaceuticals (RXRX) is back in focus after management detailed AI driven gains in drug discovery, including 25 new targets identified at once, as investors look ahead to an earnings report with expectations for tighter losses and higher revenue. See our latest analysis for Recursion Pharmaceuticals. Despite the recent 6.17% single day share price decline to US$3.50 and a weaker 1 year total shareholder return of 39.13%, the 10.41% 1 month share price gain hints that sentiment...